CAS: 37091-73-9; 2-Chloro-1,3-Dimethylimidazolinium Chloride

相似化合物

153433-26-2 101385-69-7 1029633-62-2

上下游产品

CAS号80-73-9 1,3-二甲基-2-咪唑啉酮 | CAS号1911-01-9 2-(1,3-dimethyl... | CAS号65523-28-6 SiCl(2,4,6-trim... | CAS号75-44-5 光气 | CAS号79-37-8 草酰氯 | CAS号90753-14-3 chloro-tris(2,3... | CAS号65523-26-4 tris(2,6-dimeth... | CAS号90753-15-4 Germane, chloro... | CAS号62120-68-7 chloro-tris(2,4... | CAS号37441-29-5 5-氨基-2,4,6-三碘异酞酰氯 | CAS号207855-09-2 1,3-dimethyl-N-... | CAS号98-59-9 对甲苯磺酰氯(PTSC) | CAS号80-73-9 1,3-二甲基-2-咪唑啉酮 | CAS号112-16-3 十二酰氯 | CAS号28141-24-4 对羟基苯甲酰氯 | CAS号100-20-9 对苯二甲酰氯 | CAS号14667-47-1 2-氨基吡啶-3-甲酸甲酯 | CAS号101385-69-7 2-氯-1,3-二甲基咪唑六氟磷酸盐 | CAS号220405-40-3 2,2-二氟-1,3-二甲基咪唑烷

1,3-二甲基-2-咪唑啉酮置于草酰氯体系中,用 四氯化碳 用作溶剂,以75%的收率获得2-氯-1,3-二甲基氯化咪唑啉
参考文献:4-胍基吡啶在酰化反应中的催化潜力
标题:4-胍基吡啶在酰化反应中的催化潜力
摘要:已经合成了一系列具有可变烷基化模式的3-烷基-4-胍基吡啶,并就其在醇的酰化反应中的催化潜力进行了表征.在mp2(fc)/ 6-31 + G(2D,P)// B98处评估了取代模式稳定酰基吡啶鎓阳离子的能力,酰基吡啶鎓阳离子是吡啶催化的酰化反应催化循环中的关键中间体. / 6-31G(d)的理论水平,并使用pcm连续溶剂化模型将溶剂效应包括在氯仿中.最具活性的4-胍基吡啶是具有最富电子的吡啶环的那些.还研究了辅助碱的类型和浓度对催化活性的影响.从三乙胺变为n,N-二异丙基乙胺作为辅助碱不会导致催化速率的系统增加或降低,完全不存在辅助碱会导致反应速率降低27倍. 酯化-Lewis碱-从头算计算-动力学
Doi:10.1055/s-0029-1216830

专利信息

专利号:WO-2024185734-A1
优先权日:2023-03-03
标 题:Polyphosphorylated nucleoside, phosphate-activated nucleotide used for synthesis of polyphosphorylated nucleoside and method for synthesis of same, and method for synthesis of polyphosphorylated nucleoside using phosphate-activated nucleotide
发明人：KATAOKA MASANORI; FUKUI CHIHARU; TSUJI YOHEI; FUJIMURA Kazuma
权利人:NATIAS INC
摘要:The present invention provides: a polyphosphorylated nucleoside which has a structure represented by formula (I) and can be efficiently produced by a short process and a simple operation with use of a less expensive material; a phosphate-activated nucleotide which is used for the synthesis of the polyphosphorylated nucleoside and a method for the synthesis of this phosphate-activated nucleotide; and a method for the synthesis of a polyphosphorylated nucleoside using a phosphate-activated nucleotide. In the formula, B represents a protected or unprotected, natural or artificial nucleoside base; R 1 , R 2 , R 4 and R 5 each represent H or an alkyl group or the like, and R 1 , R 2 , R 4 and R 5 may be the same as or different from each other; X and Y each represents H, OH, OCH 3 or the like; h represents an integer of 1 to 3; p, n, m and q each represent 0 or an integer, and p, n, m and q are in no particular order; and (p + n + m + q) is an integer of 0 to 5,000.

专利号:US-12240835-B2
优先权日:2018-09-18
标题:Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity
发明人：ROMERO F ANTHONY; KIRSCHBERG THORSTEN A; HALCOMB RANDALL; XU YINGZI
权利人:TERNS PHARMACEUTICALS INC
摘要:Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

专利号:US-6384228-B2
优先权日:1998-05-26
标题 :Method for synthesis of halopyridyl-azacyclopentane derivative and intermediate thereof
发明人：NODE MANABU; NAKAMURA DAISAKU; FUJIWARA TOSHIO; ICHIHASHI SHOGO
权利人:NIHON MEDIPHYSICS CO LTD
摘要:The present invention relates to a method for synthesis of an optically active halopyridyl-azacyclo-pentane derivative and the intermediate thereof which comprises preparing an optically active allene-1,3-dicarboxylic acid ester derivative from an optically active acetonedicarboxylic acid ester derivative and then proceeding through a 7-azabicyclo[2.2.1]heptane derivative to obtain the objective product.

专利号:US-2010159540-A1
优先权日:2007-03-26
标题:Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof
发明人：RODRIGUEZ ANA; SPUR BERND
权利人:RODRIGUEZ ANA; SPUR BERND
摘要:Methods are disclosed for the preparation of a new class of lipid mediators known as resolvins, with Resolvin D6 (4,17-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) being exemplary. Also disclosed are methods for the efficient synthesis of key intermediates in the preparation of such resolvins, such as isotopically labeled ω-3 fatty acid metabolites, and derivatives and analogs thereof. The invention likewise extends to the intermediates so prepared, and to the resolvins prepared with their use.

专利号:US-9938282-B2
优先权日:2014-02-05
标 题:Expedient synthesis of sitagliptin
发明人：JANAGANI SATYANARAYANA; THADURI VENKATESHWAR KUMAR; VAMARAJU RAVISANKAR
权利人:STEREOKEM INC
摘要:Novel intermediates are disclosed as intermediates for preparation of a Sitagliptin. A novel synthetic method to prepare Sitagliptin using the said intermediates is also disclosed.

专利号:US-8063062-B2
优先权日:2006-12-20
标 题 :Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
发明人：LANGE JOSEPHUS H M; KRUSE CORNELIS G; SHADID BELAL
权利人:LANGE JOSEPHUS H M; KRUSE CORNELIS G; SHADID BELAL; SOLVAY PHARM BV
摘要:Embodiments of this invention relate to compounds having a combination of cannabinoid-CB 1 antagonism and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing novel intermediates useful for the synthesis of these compounds, and methods for preparing compositions comprising these compounds. The invention also relates to methods of treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction or substance abuse by administering a pharmaceutical composition comprising these compounds to a patient in need thereof. A compound with a combination of cannabinoid-CB 1 antagonism and cholinesterase inhibition is a compound of formula (1) n nwherein the symbols have the meanings given in the specification.